Aimmune Therapeutics (AIMT) Earning Favorable Press Coverage, Study Shows
News coverage about Aimmune Therapeutics (NASDAQ:AIMT) has trended positive recently, according to AlphaOne Sentiment Analysis. The research firm, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aimmune Therapeutics earned a daily sentiment score of 0.29 on AlphaOne’s scale. AlphaOne also gave news headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s scoring:
- Aimmune Therapeutics Inc (AIMT) Upgraded by Zacks Investment Research to “Buy” (americanbankingnews.com)
- Insider Trading Activity Aimmune Therapeutics Inc (NASDAQ:AIMT) – CFO Bought 5,000 shares of Stock (4-traders.com)
- Why These Drug Stocks May Surge (finance.yahoo.com)
- Eric Bjerkholt Acquires 5,000 Shares of Aimmune Therapeutics Inc (AIMT) Stock (americanbankingnews.com)
- Insider Trading Activity Aimmune Therapeutics Inc (NASDAQ:AIMT) – insider Sold 600 shares of Stock (4-traders.com)
Aimmune Therapeutics (NASDAQ:AIMT) opened at 19.04 on Friday. The firm has a 50-day moving average price of $19.76 and a 200 day moving average price of $20.84. Aimmune Therapeutics has a one year low of $9.77 and a one year high of $27.31. The company’s market cap is $958.51 million.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.05. Equities analysts expect that Aimmune Therapeutics will post ($2.64) earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on AIMT shares. Piper Jaffray Companies reissued an “overweight” rating and issued a $40.00 price target on shares of Aimmune Therapeutics in a research note on Monday, February 13th. Wedbush reaffirmed an “outperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Friday, February 17th. Finally, Zacks Investment Research cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 20th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $33.20.
ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/05/19/aimmune-therapeutics-aimt-earning-favorable-press-coverage-study-shows.html.
In related news, CFO Warren L. Desouza sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $21.58, for a total value of $323,700.00. Following the sale, the chief financial officer now owns 35,681 shares in the company, valued at approximately $769,995.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Warren L. Desouza sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 21st. The stock was sold at an average price of $22.95, for a total value of $229,500.00. Following the completion of the sale, the chief financial officer now owns 30,681 shares in the company, valued at approximately $704,128.95. The disclosure for this sale can be found here. Insiders have sold a total of 25,600 shares of company stock worth $565,290 in the last quarter. Company insiders own 24.56% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related stocks with our FREE daily email newsletter.